Developer docs
API playgroundTry for free, no card

Search company profiles

VentriPoint Diagnostics

Full company profile

uuid0005vd8

Namestring
VentriPoint Diagnostics
Legal namestring
Ventripoint Diagnostics Ltd.
Websiteurl
ventripoint.com
Company typeenum
Public
Founded yearint
2001
Descriptiontext

Ventripoint Diagnostics Ltd. is a publicly traded Canadian medical technology company (TSXV:VPT, OTCQB:VPTDF) headquartered in Toronto that develops the VMS+ platform, an AI-powered cardiac imaging system designed to convert standard 2D echocardiograms into MRI-quality 3D volumetric models of all four heart chambers. Its core technology, the patented Knowledge-Based Reconstruction (KBR) algorithm, combines anatomical landmark detection on 2D echo images with an MRI-validated reference library of normal and pathological adult and pediatric heart morphologies. The latest generation, VMS+ 4.0, adds AI-assisted landmark placement that reduces analysis time by approximately 30% and includes a Global Longitudinal Strain module; the platform integrates with PACS/DICOM and standard ultrasound machines via a proprietary sensor tracking system. Ventripoint holds regulatory clearances in Canada (Health Canada, August 2024), Europe (CE Mark under EU MDR, October 2024), and the United States (FDA 510(k), February 2025), and is pursuing China NMPA approval through partner Lishman Global.

The company serves primarily congenital heart disease (CHD) and pediatric cardiology programs, with secondary applications in pulmonary hypertension, cardiotoxicity surveillance, heart failure, valve disease, and remote/Indigenous community care via hub-and-spoke models. Named customers include Duke University Health Center, German Heart Center Berlin, University of Freiburg Medical Center, Guy's and St Thomas' NHS Foundation Trust, East Midlands Congenital Heart Centre, Evelina London Children's Hospital, and Hospital Metropolitano in Costa Rica. The business model is transitioning from one-time capital equipment sales toward a Device-as-a-Service subscription targeting an 80/20 recurring mix, distributed through regional channel partners (Cardiologic UK, AngioPRO Germany, Lishman Global China), platform integrators (ASCEND Cardiovascular Gen3Echo, LG Consulting Solutions), and emerging markets partners (Montecristo Group, First Light Health). With a current installed base of approximately 25 systems targeted to double to 50, headcount of 11-50 employees, and revenue expected to begin accruing in Q2 2026, Ventripoint is in the early commercial scaling phase following two decades of product development.

Short descriptiontext

Ventripoint Diagnostics is a Canadian public medtech company that sells the AI-powered VMS+ platform, converting standard 2D echocardiograms into MRI-quality 3D heart models for congenital heart disease, pediatric cardiology, and pulmonary hypertension programs at hospitals and remote community health sites globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac imaging software, 3D echocardiography platform, AI heart diagnostics, congenital heart disease imaging, knowledge-based reconstruction
Industry4 codes
PRIMARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLACALAE
Imaging Workflow Orchestration & Modality Worklist (MWL)/Scheduling
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAKABAE
Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear)
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Diagnostic Imaging Software
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Device-as-a-Service Subscription
TypeSubscription Recurring
Description

Transitioning from capital equipment sales to subscription model (Device-as-a-Service). Monthly or annual subscription for VMS+ software access with ongoing support and updates. Target is 80/20 weighting toward subscription over direct capital purchases.

ventripoint.com
2Capital Equipment Sales
TypeOne Time License
Description

Traditional one-time capital purchase of VMS+ systems. Currently transitioning to subscription model but maintains flexibility for sites preferring capital purchases.

ventripoint.com
3Future Cost-per-Use Model
TypeUsage Based
Description

Long-term plan to shift to cost-per-use model as procedure volumes increase, allowing scaling based on actual usage.

ventripoint.com
4Hardware/Component Sales
TypeHardware Sales
Description

Sale of VMS+ hardware systems including sensors and installation components. Company ordered components for 25 systems to support near-term deployment.

ventripoint.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels9 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Pricing details2 tiers
1Device-as-a-Service Subscription Model
ModelSubscriptionBilling cadenceAnnual
Notes

Monthly or annual subscription for VMS+ access. Target weighting of 80% of new deployments. Provides ongoing software updates, support, and training.

ventripoint.com
2Capital Equipment Purchase
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Traditional one-time purchase model for VMS+ systems. Available for sites preferring capital purchases over subscription.

ventripoint.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1VMS+™
Description

AI-powered cardiac imaging platform that transforms standard 2D echocardiograms into MRI-quality 3D heart models using Knowledge-Based Reconstruction (KBR) technology. Provides volumetric measurements and ejection fractions for all four chambers of the heart.

ventripoint.com
+1 more record
Core offering1 text field

VentriPoint Diagnostics develops and sells the VMS+ cardiac imaging platform, an AI-powered system that transforms standard 2D echocardiograms into MRI-quality 3D models of the heart. The proprietary Knowledge-Based Reconstruction (KBR) algorithm provides volumetric measurements and ejection fractions for all four heart chambers with cMRI-equivalent accuracy. The platform includes the VMS+ hardware/software system with sensor tracking, a workstation-based 3D Echo and MRI software, and add-on modules such as Global Longitudinal Strain analysis, targeting hospitals, cardiac centers, and remote healthcare providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 98% task completion rate with no critical errors in usability study
+6 more records
Product overview1 text field

VentriPoint Diagnostics offers the VMS+ cardiac imaging platform, a unified system comprising software that transforms standard 2D echocardiograms into MRI-quality 3D heart models using proprietary Knowledge-Based Reconstruction (KBR) algorithms. The core VMS+ platform provides volumetric measurements and ejection fractions for all four heart chambers, with particular strength in assessing the difficult-to-image right ventricle. The portfolio includes: (1) VMS+ hardware/software platform that connects to standard ultrasound machines with sensor tracking, (2) VMS+ 3D Echo and MRI Software for workstation installation, and (3) VMS+ Global Longitudinal Strain add-on module. The system is designed for point-of-care use, remote installation capability, and provides results in a three-step workflow within minutes.

Product and service3 records
1VMS+ (Vision Medical System Plus)
CategoryCardiac Imaging Software Platform
Description

AI-powered cardiac imaging platform that transforms standard 2D echocardiograms into accurate 3D models of the heart, providing volumetric measurements and ejection fractions for all four chambers with MRI-equivalent accuracy. Designed for point-of-care use with hardware sensor tracking system.

2VMS+ 3D Echo and MRI Software
CategoryCardiac Imaging Software
Description

Software application that can be installed on any personal workstation to create 3D models of the heart from commercially available 3D echo or MRI images, providing reproducible and accurate volumetric measurements and ejection fractions.

3VMS+ Global Longitudinal Strain
CategoryCardiac Analysis Module
Description

Advanced analysis module that provides 3D-based global longitudinal strain measurements by combining motion data from the whole 3D model into a single measure, without requiring additional images or software licenses.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Digital stethoscope and cardiac AI company offering FDA-cleared algorithms for heart murmur and AF detection from auscultation. Comparable as an emerging cardiac AI diagnostics player, although it competes at the primary-care/screening layer rather than the specialist echo layer Ventripoint addresses.

TypeBroad incumbent
Description

Major cardiac ultrasound vendor (ACUSON SC2000, echo AI features) with broad imaging informatics portfolio. Comparable as a large incumbent that could compete with or absorb Ventripoint-style AI echo quantification functionality inside its installed base.

TypeDirect peer
Description

AI-driven cardiac MRI acquisition and analysis company (FDA-cleared One Click MRI), focused on automating CMR workflows. Comparable in target user (cardiologists) and the thesis of bringing faster, more reproducible cardiac imaging to point of care.

TypeDirect peer
Description

Singapore-based AI echocardiography company with FDA-cleared, fully automated echo analysis software that produces measurements comparable to cardiac MRI. Closely comparable in product (AI echo → MRI-quality measurements) and target customers (cardiology departments and clinical trials).

TypeEmerging player
Description

Digital cardiac ambulatory monitoring company (Zio) using AI on ECG patch data for arrhythmia detection. Comparable as a digitally enabled cardiac diagnostics company selling into cardiology with recurring-revenue economics, although addressing arrhythmia rather than structural/volumetric assessment.

TypeDirect peer
Description

UK-based AI echocardiography company offering EchoGo, an FDA-cleared platform that automates cardiac ultrasound analysis and decision support. Directly comparable to Ventripoint as a pure-play AI software company targeting AI-driven quantification on top of standard echo machines in cardiology.

TypeEmerging player
Description

AI cardiac CT company providing automated plaque quantification and coronary assessment. Adjacent emerging player applying AI to non-invasive cardiac imaging quantification, with overlapping customer (cardiology departments) but different modality (CT vs echo).

TypeBroad incumbent
Description

Global incumbent in cardiac ultrasound with integrated AI tools for automated quantification (e.g., Cardiac True Vue, AI-enabled measurements on EPIQ/EchoNavigator). Comparable as a competitor embedding AI cardiac analytics into the dominant hospital imaging platform.

9Caption Health (Caption AI, GE HealthCare)
TypeBroad incumbent
Description

Originally an AI-guided cardiac ultrasound software company (Caption AI) acquired by GE HealthCare in 2023. Now embedded in GE's ultrasound ecosystem as part of its broader portfolio, providing automated cardiac measurement tools at scale across the largest installed base in cardiac ultrasound.

TypeDirect peer
Description

Calgary-based cardiac imaging software company providing CMR (cardiac MRI) and CT post-processing tools used in congenital and structural heart disease. Closely comparable in clinical use case (advanced cardiac quantification, congenital heart disease workflows) though focused on MRI/CT rather than echo.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VentriPoint Diagnostics

Cardiac Diagnostic Imaging Softwareventripoint.com

Ventripoint Diagnostics is a Canadian public medtech company that sells the AI-powered VMS+ platform, converting standard 2D echocardiograms into MRI-quality 3D heart models for congenital heart disease, pediatric cardiology, and pulmonary hypertension programs at hospitals and remote community health sites globally.

What VentriPoint Diagnostics does

Ventripoint Diagnostics Ltd. is a publicly traded Canadian medical technology company (TSXV:VPT, OTCQB:VPTDF) headquartered in Toronto that develops the VMS+ platform, an AI-powered cardiac imaging system designed to convert standard 2D echocardiograms into MRI-quality 3D volumetric models of all four heart chambers. Its core technology, the patented Knowledge-Based Reconstruction (KBR) algorithm, combines anatomical landmark detection on 2D echo images with an MRI-validated reference library of normal and pathological adult and pediatric heart morphologies. The latest generation, VMS+ 4.0, adds AI-assisted landmark placement that reduces analysis time by approximately 30% and includes a Global Longitudinal Strain module; the platform integrates with PACS/DICOM and standard ultrasound machines via a proprietary sensor tracking system. Ventripoint holds regulatory clearances in Canada (Health Canada, August 2024), Europe (CE Mark under EU MDR, October 2024), and the United States (FDA 510(k), February 2025), and is pursuing China NMPA approval through partner Lishman Global.

The company serves primarily congenital heart disease (CHD) and pediatric cardiology programs, with secondary applications in pulmonary hypertension, cardiotoxicity surveillance, heart failure, valve disease, and remote/Indigenous community care via hub-and-spoke models. Named customers include Duke University Health Center, German Heart Center Berlin, University of Freiburg Medical Center, Guy's and St Thomas' NHS Foundation Trust, East Midlands Congenital Heart Centre, Evelina London Children's Hospital, and Hospital Metropolitano in Costa Rica. The business model is transitioning from one-time capital equipment sales toward a Device-as-a-Service subscription targeting an 80/20 recurring mix, distributed through regional channel partners (Cardiologic UK, AngioPRO Germany, Lishman Global China), platform integrators (ASCEND Cardiovascular Gen3Echo, LG Consulting Solutions), and emerging markets partners (Montecristo Group, First Light Health). With a current installed base of approximately 25 systems targeted to double to 50, headcount of 11-50 employees, and revenue expected to begin accruing in Q2 2026, Ventripoint is in the early commercial scaling phase following two decades of product development.

VentriPoint Diagnostics firmographics

Firmographics
Name
VentriPoint Diagnostics
Legal name
Ventripoint Diagnostics Ltd.
Website
https://ventripoint.com
Company type
Public
Founded year
2001
Operating status
Operating
Headcount range
11–50 employees
Short description
Ventripoint Diagnostics is a Canadian public medtech company that sells the AI-powered VMS+ platform, converting standard 2D echocardiograms into MRI-quality 3D heart models for congenital heart disease, pediatric cardiology, and pulmonary hypertension programs at hospitals and remote community health sites globally.
Ownership category
akta.pro rank

VentriPoint Diagnostics industry classification

Industry
Product category
Cardiac Diagnostic Imaging Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLACALAE
Imaging Workflow Orchestration & Modality Worklist (MWL)/Scheduling
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAKABAE
Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear)
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Cardiac imaging software
  • 3D echocardiography platform
  • AI heart diagnostics
  • Congenital heart disease imaging
  • Knowledge-based reconstruction

Where VentriPoint Diagnostics is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices3 records

Markets served

VentriPoint Diagnostics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Device-as-a-Service Subscription: Transitioning from capital equipment sales to subscription model (Device-as-a-Service). Monthly or annual subscription for VMS+ software access with ongoing support and updates. Target is 80/20 weighting toward subscription over direct capital purchases.
  2. Capital Equipment Sales: Traditional one-time capital purchase of VMS+ systems. Currently transitioning to subscription model but maintains flexibility for sites preferring capital purchases.
  3. Future Cost-per-Use Model: Long-term plan to shift to cost-per-use model as procedure volumes increase, allowing scaling based on actual usage.
  4. Hardware/Component Sales: Sale of VMS+ hardware systems including sensors and installation components. Company ordered components for 25 systems to support near-term deployment.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualDevice-as-a-Service Subscription Model
One time/ perpetual licenseMulti-year contractCapital Equipment Purchase

Go-to-market motion4 records

Distribution channels9 records

Marketing channels8 records

VentriPoint Diagnostics product offering

Product offering

Core offering

VentriPoint Diagnostics develops and sells the VMS+ cardiac imaging platform, an AI-powered system that transforms standard 2D echocardiograms into MRI-quality 3D models of the heart. The proprietary Knowledge-Based Reconstruction (KBR) algorithm provides volumetric measurements and ejection fractions for all four heart chambers with cMRI-equivalent accuracy. The platform includes the VMS+ hardware/software system with sensor tracking, a workstation-based 3D Echo and MRI software, and add-on modules such as Global Longitudinal Strain analysis, targeting hospitals, cardiac centers, and remote healthcare providers.

Product overview

VentriPoint Diagnostics offers the VMS+ cardiac imaging platform, a unified system comprising software that transforms standard 2D echocardiograms into MRI-quality 3D heart models using proprietary Knowledge-Based Reconstruction (KBR) algorithms. The core VMS+ platform provides volumetric measurements and ejection fractions for all four heart chambers, with particular strength in assessing the difficult-to-image right ventricle. The portfolio includes: (1) VMS+ hardware/software platform that connects to standard ultrasound machines with sensor tracking, (2) VMS+ 3D Echo and MRI Software for workstation installation, and (3) VMS+ Global Longitudinal Strain add-on module. The system is designed for point-of-care use, remote installation capability, and provides results in a three-step workflow within minutes.

Differentiator

Problem solved

Functional benefit

Brands

  • VMS+™: AI-powered cardiac imaging platform that transforms standard 2D echocardiograms into MRI-quality 3D heart models using Knowledge-Based Reconstruction (KBR) technology. Provides volumetric measurements and ejection fractions for all four chambers of the heart.
  • VMS+ 4.0

Products and services

  • VMS+ (Vision Medical System Plus) AI-powered cardiac imaging platform that transforms standard 2D echocardiograms into accurate 3D models of the heart, providing volumetric measurements and ejection fractions for all four chambers with MRI-equivalent accuracy. Designed for point-of-care use with hardware sensor tracking system.
  • VMS+ 3D Echo and MRI Software Software application that can be installed on any personal workstation to create 3D models of the heart from commercially available 3D echo or MRI images, providing reproducible and accurate volumetric measurements and ejection fractions.
  • VMS+ Global Longitudinal Strain Advanced analysis module that provides 3D-based global longitudinal strain measurements by combining motion data from the whole 3D model into a single measure, without requiring additional images or software licenses.

Quantifiable outcome

  • 98% task completion rate with no critical errors in usability study
  • +6 more outcomes

Companies that use VentriPoint Diagnostics

Customer profile

Named customers10 records

Segments6 records

Ideal customer profiles3 records

VentriPoint Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature6 records

VentriPoint Diagnostics partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves12 records

Expansion highlights8 records

VentriPoint Diagnostics competitors and assessment

Company assessment

Emerging players

  • Eko Health: Digital stethoscope and cardiac AI company offering FDA-cleared algorithms for heart murmur and AF detection from auscultation. Comparable as an emerging cardiac AI diagnostics player, although it competes at the primary-care/screening layer rather than the specialist echo layer Ventripoint addresses.
  • iRhythm Technologies: Digital cardiac ambulatory monitoring company (Zio) using AI on ECG patch data for arrhythmia detection. Comparable as a digitally enabled cardiac diagnostics company selling into cardiology with recurring-revenue economics, although addressing arrhythmia rather than structural/volumetric assessment.
  • Cleerly: AI cardiac CT company providing automated plaque quantification and coronary assessment. Adjacent emerging player applying AI to non-invasive cardiac imaging quantification, with overlapping customer (cardiology departments) but different modality (CT vs echo).

Broad incumbents

  • Siemens Healthineers (Cardiac Ultrasound): Major cardiac ultrasound vendor (ACUSON SC2000, echo AI features) with broad imaging informatics portfolio. Comparable as a large incumbent that could compete with or absorb Ventripoint-style AI echo quantification functionality inside its installed base.
  • Philips (Cardiac Ultrasound / AI): Global incumbent in cardiac ultrasound with integrated AI tools for automated quantification (e.g., Cardiac True Vue, AI-enabled measurements on EPIQ/EchoNavigator). Comparable as a competitor embedding AI cardiac analytics into the dominant hospital imaging platform.
  • Caption Health (Caption AI, GE HealthCare): Originally an AI-guided cardiac ultrasound software company (Caption AI) acquired by GE HealthCare in 2023. Now embedded in GE's ultrasound ecosystem as part of its broader portfolio, providing automated cardiac measurement tools at scale across the largest installed base in cardiac ultrasound.

Direct peers

  • HeartVista: AI-driven cardiac MRI acquisition and analysis company (FDA-cleared One Click MRI), focused on automating CMR workflows. Comparable in target user (cardiologists) and the thesis of bringing faster, more reproducible cardiac imaging to point of care.
  • Us2.ai: Singapore-based AI echocardiography company with FDA-cleared, fully automated echo analysis software that produces measurements comparable to cardiac MRI. Closely comparable in product (AI echo → MRI-quality measurements) and target customers (cardiology departments and clinical trials).
  • Ultromics: UK-based AI echocardiography company offering EchoGo, an FDA-cleared platform that automates cardiac ultrasound analysis and decision support. Directly comparable to Ventripoint as a pure-play AI software company targeting AI-driven quantification on top of standard echo machines in cardiology.
  • Circle Cardiovascular Imaging: Calgary-based cardiac imaging software company providing CMR (cardiac MRI) and CT post-processing tools used in congenital and structural heart disease. Closely comparable in clinical use case (advanced cardiac quantification, congenital heart disease workflows) though focused on MRI/CT rather than echo.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

VentriPoint Diagnostics social profiles

Digital presence

VentriPoint Diagnostics compliance and trust

Trust signal

Compliance3 records

VentriPoint Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VentriPoint Diagnostics leadership team

Management profile

Number of profiles

Profiles9 records

VentriPoint Diagnostics funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VentriPoint Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VentriPoint Diagnostics

What does VentriPoint Diagnostics do?

VentriPoint Diagnostics develops and sells the VMS+ cardiac imaging platform, an AI-powered system that transforms standard 2D echocardiograms into MRI-quality 3D models of the heart. The proprietary Knowledge-Based Reconstruction (KBR) algorithm provides volumetric measurements and ejection fractions for all four heart chambers with cMRI-equivalent accuracy. The platform includes the VMS+ hardware/software system with sensor tracking, a workstation-based 3D Echo and MRI software, and add-on modules such as Global Longitudinal Strain analysis, targeting hospitals, cardiac centers, and remote healthcare providers.

Is VentriPoint Diagnostics a public or private company?

VentriPoint Diagnostics is a public company. It is classified as public and is currently operating.

When was VentriPoint Diagnostics founded?

VentriPoint Diagnostics was founded in 2001. It employs 11 to 50 people.

Where is VentriPoint Diagnostics based?

VentriPoint Diagnostics is headquartered in Toronto, Canada, in the North America region.

How does VentriPoint Diagnostics make money?

Four revenue lines are on record. Device-as-a-Service Subscription is the primary driver. The others are capital Equipment Sales, future Cost-per-Use Model and hardware/Component Sales.

Who are VentriPoint Diagnostics's main competitors?

Emerging players on record are Eko Health, iRhythm Technologies and Cleerly. Broad incumbents are Siemens Healthineers (Cardiac Ultrasound), Philips (Cardiac Ultrasound / AI) and Caption Health (Caption AI, GE HealthCare). Direct peers are HeartVista, Us2.ai, Ultromics and Circle Cardiovascular Imaging.

Does VentriPoint Diagnostics have an API?

No public API is recorded for VentriPoint Diagnostics.

What industry is VentriPoint Diagnostics in?

VentriPoint Diagnostics's product category is Cardiac Diagnostic Imaging Software. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT), with a secondary code of HLACALAE, Imaging Workflow Orchestration & Modality Worklist (MWL)/Scheduling. Its NAICS code is 54151 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
stockhouseVentripoint sells two VMS+ cardiac imaging systems for donationVentripoint Diagnostics sold two VMS+ cardiac imaging systems to be donated in honor of Ella's Umbrella. One system will support a study of pregnant women with congenital heart disease, and the other will be used in routine clinical practice to assess workflow integration. The company expects the experience to inform future deployments.TradingViewVentripoint Diagnostics Announces Placement of Two VMS+™ Systems for Clinical DeploymentVentripoint Diagnostics announced the donation of two VMS+ cardiac imaging systems in honor of Ella's Umbrella. One system will support a study on pregnant women with congenital heart disease, and the other will be deployed in routine clinical practice. The company expects these placements to inform future deployments and support broader acceptance of VMS+.TradingViewVentripoint Diagnostics Ltd. (VPT) Sells Two VMS+ Systems for Clinical DeploymentVentripoint Diagnostics sold two VMS+ cardiac imaging systems for donation in honor of Ella's Umbrella. One system is planned for a study on pregnant women with congenital heart disease, the other for routine clinical practice. No sale value or study results are disclosed.Business & FinancialVentripoint Diagnostics LtdVentripoint Diagnostics Ltd closed the second and final tranche of its non-brokered private placement, issuing 2,224,250 units at $0.10 each. The first tranche closed on September 8, 2026, with 1,800,000 units issued. The company's shares traded up one cent to $0.07.TradingViewVentripoint Diagnostics Ltd. (VPT) Raises $222,425 in Final Placement TrancheVentripoint Diagnostics closed its final private placement tranche, issuing 2,224,250 units at $0.10 each for $222,425. The units include shares and warrants, with insiders subscribing for 460,000 units. The placement awaits final TSXV approval.The future of tradingVentripoint Announces Extension of Non-Brokered Unit Private PlacementVentripoint Diagnostics announced an extension of its non-brokered private placement to up to 3.5 million units at $0.10 each, with each unit comprising a share and a warrant. Proceeds will fund commercialization, technology advancement, and working capital. The offering is subject to TSXV approval.TradingViewVentripoint Announces Extension of Non-Brokered Unit Private PlacementVentripoint Diagnostics announced an extension of its non-brokered private placement to up to 3.5 million units at $0.10 each, with the first tranche closing September 8, 2026. Proceeds will fund commercialization, technology advancement, and working capital. The offering is subject to TSXV approval and a four-month hold period.TradingViewVentripoint Diagnostics Ltd. (VPT) Seeks Extension of $0.10 Unit FinancingVentripoint Diagnostics Ltd. is seeking TSXV approval to extend its non-brokered offering of up to 3.5 million units at $0.10 each, with warrants at $0.14 for 24 months. The first tranche closed on Sept. 8, 2026, and proceeds will fund commercialization and operations.Seeking AlphaVentripoint Diagnostics Ltd. (VPT:CA) Shareholder/Analyst Call TranscriptVentripoint's CEO Hugh MacNaught outlined the company's shift from technology development to commercialization, focusing on its AI-enhanced echocardiography platform VMS. VMS delivers cardiac volumetric measurements with MRI-comparable accuracy and is approved in the U.S., Europe, and Canada, with approval pending in China.FinancialContent Business PageUniDoc Health Signs MOU with Ventripoint Diagnostics to Evaluate Remote Cardiac Assessment and Screening PlatformUniDoc Health Corp. and Ventripoint Diagnostics Ltd. have signed a non-binding memorandum of understanding to evaluate a potential collaboration integrating Ventripoint's AI-enabled cardiac imaging platform with UniDoc's connected-care infrastructure. The proposed hub-and-spoke model aims to facilitate remote cardiac assessment and screening in underserved communities by combining community-based image acquisition with specialist cardiology review. Initial activities will focus on identifying pilot sites, assessing technical requirements, and defining workflows for potential future deployment.